Holen Sie sich die Stockscreener-App
17.08
0.06%
0.010
Handel nachbörslich:
17.16
0.08
+0.47%
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Is Denali Therapeutics Inc. stock a good choice for value investors2025 Technical Patterns & Daily Volume Surge Trade Alerts - ulpravda.ru
What insider trading reveals about Denali Therapeutics Inc. stockRecession Risk & AI Powered Market Trend Analysis - ulpravda.ru
Investment Recap: Is Denali Therapeutics Inc stock recession proof2025 Top Gainers & Precise Buy Zone Identification - moha.gov.vn
Why analysts upgrade Denali Therapeutics Inc. stockQuarterly Trade Report & Low Drawdown Momentum Trade Ideas - ulpravda.ru
What RSI levels show for Denali Therapeutics Inc. (4DN) stockJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - ulpravda.ru
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - ulpravda.ru
Denali Therapeutics CEO Ryan J. Watts Sells Shares - TradingView — Track All Markets
Is Denali Therapeutics Inc. stock recession proofJuly 2025 Final Week & AI Powered Buy and Sell Recommendations - ulpravda.ru
Will Denali Therapeutics Inc. stock reach all time highs in 2025Quarterly Market Summary & Long-Term Growth Plans - ulpravda.ru
What risks investors should watch in Denali Therapeutics Inc. stockStochastic Oscillator Alerts & Outstanding Profit Investment - ulpravda.ru
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - Yahoo Finance
The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review - Yahoo Finance
Performance Recap: Will Denali Therapeutics Inc. stock reach all time highs in 20252025 EndofYear Setup & Risk Managed Investment Entry Signals - moha.gov.vn
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up - sharewise.com
Will Denali Therapeutics Inc. stock see insider buyingMarket Depth Overview & Unlock Patterns Humans Can’t See - ulpravda.ru
Denali Therapeutics outlines key milestones for 2026 By Investing.com - Investing.com Nigeria
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential - Investing.com South Africa
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flows2026 world cup usa national team round of 32 young talents transition play winner prediction expert opinion - ulpravda.ru
Denali Prepares For Key Clinical And Regulatory Milestones - Nasdaq
Denali Therapeutics announces key anticipated milestones and priorities for 2026 - MarketScreener
Denali Therapeutics outlines key milestones for 2026 - Investing.com
Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision - TipRanks
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome - The Manila Times
Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026 - TradingView — Track All Markets
Hunter syndrome drug nears FDA decision as new brain therapies move ahead - Stock Titan
Denali Therapeutics Inc. (DNLI) Stock Analysis: A Biotech Powerhouse with 101% Upside Potential - DirectorsTalk Interviews
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - MSN
Denali Therapeutics Earnings Notes - Trefis
Smart Money: Is Denali Therapeutics Inc stock recession proofM&A Rumor & Daily Technical Stock Forecast Reports - moha.gov.vn
Hunter Syndrome Treatment Market is expected to reach US$ - openPR.com
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential By Investing.com - Investing.com Nigeria
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial - Investing.com Nigeria
Understanding Momentum Shifts in (DNLI) - Stock Traders Daily
Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence - Investing.com Nigeria
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial By Investing.com - Investing.com South Africa
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - The Manila Times
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewswire Inc.
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
3 Biotech Stocks With Major 2026 Catalysts - Yahoo Finance
Denali Therapeutics clears technical benchmark, hitting 80-plus RS rating - MSN
What drives Denali Therapeutics Inc 4DN stock priceIPO Market Watch & Free Expert Stock Watchlists - earlytimes.in
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
BTIG reiterates Denali Therapeutics (DNLI) buy recommendation - MSN
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions - Yahoo Finance
How Investors May Respond To Denali Therapeutics (DNLI) $200 Million Equity Raise And FDA Voucher Talks - Yahoo Finance
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? - Insider Monkey
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):